kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
928
JPY
-8
(-0.85%)
Mar 13, 3:30 pm JST
5.82
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.38
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
915 JPY 5.75 USD
Previous Close Mar 12
936 JPY 5.88 USD
High Mar 13, 10:15 am
941 JPY 5.91 USD
Low Mar 13, 9:06 am
911 JPY 5.72 USD
Volume
713,300
Trading Value
0.66B JPY 4.15M USD
VWAP
926.77 JPY 5.81 USD
Minimum Trading Value
92,800 JPY 582 USD
Market Cap
0.08T JPY 0.53B USD
Number of Trades
1,367
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,287
1-Year High Dec 19, 2025
6,833
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 266,600 5,920,800 22.21
Feb 27, 2026 271,500 5,609,400 20.66
Feb 20, 2026 245,400 5,639,800 22.98
Feb 13, 2026 231,000 5,692,800 24.64
Feb 6, 2026 192,200 5,934,000 30.87
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.